HIV-1 GP 120 V1/V2 antigens and immunological uses thereof

Patent metadata

Field	Value
Publication number	US-9731002-B2
Application number	US-201314427393-A
Country	US
Kind code	B2
Filing date	Sep 11, 2013
Priority date	Sep 11, 2012
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

HIV-1 envelope proteins and fragments that possess naturally occurring and novel engineered epitopes that can be used to elicit (and are recognized by) broadly neutralizing antibodies.

First claim

The invention claimed is:

1. An immunogenic composition comprising an MN-rgp120 polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

2. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3.

3. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4.

4. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 5.

5. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 6.

6. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 7.

7. A method for producing an MN-rgp120 polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, the method comprising expressing the MN-rgp120 polypeptide in a cell line comprising a nucleic acid encoding the MN-rgp120 polypeptide.

8. The method of claim 7 , wherein the cell line lacks N-acetylglucosaminyltransferase I (GnTI) activity.

9. A method for inducing an immune response to an MN-rgp120 polypeptide in a subject, the method comprising administering the MN-rgp120 polypeptide to the subject, where the MN-rgp120 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

10. The method of claim 9 , wherein the immune response comprises generation of broadly neutralizing antibodies that bind to the MN-rgp120 polypeptide.

Assignees

• Univ California

Inventors

• Berman Phillip
• Tatsuno Gwen
• Yu Bin
• Morales Javier
• Mesa Kathryn

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/18

  for HIV · CPC title

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/21 Primary

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title